secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001140361-24-050057
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Ionis' Tryngolza (olezarsen) as first treatment for familial chylomicronemia syndrome
--------------------------------------------------------------------------------

- Phase 3 Balance trial: placebo-adjusted mean triglyceride reduction 42.5% at 6 months (p=0.0084), 57% at 12 months.
- Acute pancreatitis events: 1 patient (5%) on Tryngolza vs 7 patients (30%) on placebo over 12 months.
- Most common adverse reactions: injection site reactions (19% vs 9%), decreased platelets (12% vs 4%), arthralgia (9% vs 0%).
- U.S. launch expected before year-end; first of four independent launches planned over next three years.
- FCS affects up to ~3,000 people in U.S.; Tryngolza is self-administered monthly via auto-injector.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036124050057/0001140361-24-050057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036124050057/ef20040455_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-050057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer